CDKN2A and neoplasm: To evaluate the relationship between nonpromoter CDKN2A methylation, RNA expression and tumor progression, we assessed the risk of locoregional recurrence (LRR) for the combined cohort of (n = 69) LXSCC patients from MMC, Pittsburgh, Vanderbilt, and UNC (median follow‐up of 26 months).